TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03063866
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: fentanyl 0.5 ug/kg
Study: NCT01704196
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01298934
Drug: LBH589
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose escalation study starting at 20mg by mouth three times a week, given weekly for 24 weeks in the phase I portion of the study.
Study: NCT01449162
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01608347
Drug: LMWH+Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive a fixed dose of 40 mg of enoxaparin subcutaneous daily. Treatment will start once positive pregnancy test and will be continued until abortion or delivery (if premature), or 37 weeks of pregnancy. Additionally, 500 micrograms Folic acid tablet once daily will be started once positive pregnancy test and continues until 13 weeks' of gestation.
Study: NCT01608347
Drug: Folic Acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid 500 micrograms daily once positive pregnancy test until the 13th week of pregnancy or abortion
Study: NCT01289561
Drug: Alcohol + Caffeine Beverage
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 14 g alcohol per 180 ml total beverage combined with 60 mg caffeine per 180 ml total beverage. The alcohol and caffeine will be mixed in a fruit punch beverage. Participants may self-administer as much beverage as they like with several constraints to assure safety (e.g., participants must stop drinking if their blood alcohol content is above .12 g/dl).
Study: NCT01289561
Drug: Alcohol + Caffeine-placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14 g alcohol per 180 ml total beverage combined with 2.2 mg quinine per 180 ml total beverage. The alcohol and quinine will be mixed in a fruit punch beverage. Participants may self-administer as much beverage as they like with several constraints to assure safety (e.g., participants must stop drinking if their blood alcohol content is above .12 g/dl).
Study: NCT01284920
Drug: MDV3100
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT02484040
Drug: Two-week course of radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral capecitabine, 825mg/m2, bid
Study: NCT03086369
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV
Study: NCT01339689
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsules, bid, up to 12 weeks
Study: NCT01370902
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose administered subcutaneously (under the skin) as a comparator at all dose levels
Study: NCT01370902
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses administered subcutaneously (under the skin) as a comparator at all dose levels
Study: NCT01370902
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose administered intravenously (into a vein), as a comparator at all dose levels
Study: NCT00014040
Drug: Nitric Oxide and INOpulse Delivery System
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04127721
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02430389
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ninety seconds before pinning, an IV bolus of 10 mL of remifentanil (0.7 µg•kg-1 based on ideal body weight) will be administered from the study syringe and an IV bolus of propofol (0.7 mg•kg-1) will be administered
Study: NCT02430389
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ninety seconds before pinning, an IV bolus of 10 mL of normal saline will be administered from the study syringe and an IV bolus of propofol (0.7 mg•kg-1) will be administered
Study: NCT00572377
Drug: FemLife Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: the gel or placebo (240 mcg)applied to the vagina; 20 doses to be used over the 30 day period and to complete the Female Sexual Encounter Profile (FSEP).
Study: NCT00572377
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: the gel or placebo (240 mcg) applied to the vagina; 20 doses to be used over the 30 day period and to complete the Female Sexual Encounter Profile (FSEP).
Study: NCT02192190
Drug: LY2951742
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered subcutaneously (SC)
Study: NCT02192190
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered orally
Study: NCT00281528
Drug: ABI-007 (Abraxane)
Normalized name: PICEA ABIES WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 minute infusions
Study: NCT00605852
Drug: GSK835726
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK835726 will be available in single dose and repeat dose formulations.
Study: NCT00605852
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be given to subjects.
Study: NCT03882060
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group, no intervention.
Study: NCT02582736
Drug: typical antipsychotics
Normalized name: benzocaine Mucous Membrane Topical Solution [Topicale]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure to typical antipsychotics (M03BB02, N05AA01, N05AF03, N05AF01, N05AB02, N05AG01, N05AD01, N05AA02, N05AH01, N05AC03, N05AB03, N05AG02, N05AC04, N07XX06, N05AB05, N05AB08, N05AC02, N05AF04, N05AB06, N05AF05) will be defined as a prescription for a typical antipsychotic on the date of cohort entry.
Study: NCT00233090
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: daily dose of placebo for four weeks.
Study: NCT03688269
Drug: Intravenous saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection of 2ml Saline 0.9%
Study: NCT00003468
Drug: Antineoplaston therapy (Atengenal + Astugenal)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Children with a low grade astrocytoma that have not responded to standard therapy will receive Antineoplaston therapy (Atengenal + Astugenal).
Study: NCT02239562
Drug: sPIF
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02239562
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00655265
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets
Study: NCT01893996
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02341560
Drug: QPI-1007 Injection - 1.5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02341560
Drug: QPI-1007 Injection - 3.0 mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01402089
Drug: Caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: For phenotyping of CYP1A2, patients with non small-cell lung cancer receive additionally one-time caffeine 100mg as a tablet.
Study: NCT02064673
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo orally twice a day
Study: NCT00484055
Drug: Local application of collagen-gentamicin
Normalized name: Betagen brand of Betamethasone and Gentamicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Application of 2 sponges (5 x 20 cm) of collagen-gentamicin between the sternal halves immediately before sternal closure
Study: NCT02289118
Drug: [18F]-T807 imaging tracer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tau Imaging tracer
Study: NCT06071533
Drug: Dandshen
Normalized name: DANSHEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dandshen injection 20ml /day
Study: NCT00328822
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02358863
Drug: Modified FOLFOX6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxaliplatin 85 mg/m2 IV Day 1 every 14 days Leucovorin 400 mg/m2 IV over 2 hours Day 1 5-FU 400 mg/m2 IV over 2 hours Day 1 5-FU 2400 mg/m2 IV over 46 hours Day 1
Study: NCT00610649
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally administered matching placebo capsules.
Study: NCT01149707
Drug: PUR 0110 Rectal Enema 250 mg
Normalized name: Pur-Oxy
Approvals — FDA: no, EMA: no, PMDA: no
Description: PUR 0110 Rectal Enema 250 mg, once-daily, intrarectally
Study: NCT01149707
Drug: PUR 0110 Rectal Enema 500 mg
Normalized name: Pur-Oxy
Approvals — FDA: no, EMA: no, PMDA: no
Description: PUR 0110 Rectal Enema 500 mg, once-daily, intrarectally
Study: NCT01149707
Drug: PUR 0110 Rectal Enema 1000 mg
Normalized name: Pur-Oxy
Approvals — FDA: no, EMA: no, PMDA: no
Description: PUR 0110 Rectal Enema 1000 mg, once-daily, intrarectally
Study: NCT01149707
Drug: Placebo Enema
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Enema, once-daily, intrarectally
Study: NCT04252586
Drug: GWP42003-P
Normalized name: P
Approvals — FDA: no, EMA: no, PMDA: no
Description: GWP42003-P presented as an oral solution containing cannabidiol in the excipients sesame oil with anhydrous ethanol, sweetener (sucralose), and strawberry flavoring
Study: NCT00232180
Drug: Eplerenone
Normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eplerenone administered on top of background standard heart failure therapy
Study: NCT01295697
Drug: EZN-2208
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental
Study: NCT02748317
Drug: Lactobacillus rhamnosus GG
Normalized name: Lactobacillus rhamnosus GG
Approvals — FDA: no, EMA: no, PMDA: no
Description: For the intravesicular Lactobacillus instillation, participants will be instructed to mix the contents of 1 Lactobacillus capsule into 45 cc sterile 0.9% saline.5,6 After mixing, participants will draw up the 45 cc of the liquid Lactobacillus mixture into a 60cc catheter tip syringe and instill via the intermittent catheter after the last catheterization prior to going to bed. Participants will receive 10 Lactobacillus GG tabs at the beginning of treatment phase. At the end of each month, the coordinator or RA will ask how many remaining tablets the participant has, and if needed dispense the next supply of 10 tablets Participants will be instructed to complete the USQ-NB weekly.
Study: NCT02358863
Drug: Docetaxel/Capecitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel 30 mg/m2 IV Days 1 and 8 Capecitabine 825 mg/m2 PO BID Days 1-14
Study: NCT02358863
Drug: IRI/EPI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan IV over 90 minutes Days 1 and 8 every 28 days Epirubicin IV over 10-15 minutes Days 1 and 8 every 28 days
Study: NCT01696396
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching to abrilumab administered by subcutaneous injection
Study: NCT01925469
Drug: Benzocaine
Normalized name: Benzocaine
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01925469
Drug: Saline spray
Normalized name: Saline Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: A saline spray will be used in the placebo group
Study: NCT01718041
Drug: Experimental: VRS-317
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment arm
Study: NCT00485459
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04556539
Drug: SC10914
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400mg TID, oral admination on fasting condition
Study: NCT00278967
Drug: HalfLytely - Reformulation
Normalized name: Tarsum Reformulated
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03362216
Drug: Diclofenac Sodium Liniment
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac Sodium Liniment, apply to the affected area, 3 times a day. Course of treatment: 7 days
Study: NCT01031108
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: For the placebo product, SRT2104 drug substance will be replaced by microcrystalline cellulose (Avicel® PH 105) to match the SRT2104 investigational product.~Eight placebo capsules are stored in a dosing bottle and provided to all participating subjects for oral ingestion.
Study: NCT01031108
Drug: SRT2104
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRT2104 investigational product is a size 00 Swedish Orange opaque hard gelatin capsule containing 0.25 g of SRT2104, a new chemical entity which is supplied as a micronized, yellowish/amber powder. Eight SRT2104 capsules are stored in a dosing bottle and provided to all participating subjects for oral ingestion.
Study: NCT05296213
Drug: experimental tricalcium silicate
Normalized name: dicalcium silicate
Approvals — FDA: no, EMA: no, PMDA: no
Description: prepared tricalcium silicate paste was applied by using micro brush over the early enamel lesions on the buccal surface of the molar teeth twice daily. the patients were instructed to leave it for about 3minutes before rinsing
Study: NCT00225797
Drug: Oxymorphone Extended Release
Normalized name: oxymorphone Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01693562
Drug: MEDI4736
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive IV infusion of MEDI4736 for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
Study: NCT03643276
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Part of standard chemotherapy and included in experimental treatment phase Protocol IB long in randomization R-T
Study: NCT03643276
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Part of standard chemotherapy
Study: NCT03643276
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Part of standard chemotherapy
Study: NCT03643276
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Part of standard chemotherapy
Study: NCT03299621
Drug: Muscle Relaxant
Normalized name: MUSCLE RELAXANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monitoring of PLE value using the monitoring of PLEM™ device before and after the injection of muscle relaxant that used for tracheal intubation.
Study: NCT03932292
Drug: Ectoin Mouth Wash
Approvals — FDA: no, EMA: no, PMDA: no
Description: According to medical prescription of the instruction for use under consideration (at least 4x1 ampoule (5ml) daily, rinsed in the mouth for at least 30 seconds)
Study: NCT03932292
Drug: Supersaturated solution of calcium and phosphate ions
Approvals — FDA: no, EMA: no, PMDA: no
Description: According to medical prescription of the instruction for use under consideration (4 times a day).
Study: NCT00395746
Drug: sulfonylurea
Normalized name: Sulfonylurea
Approvals — FDA: no, EMA: no, PMDA: no
Description: SU agent
Study: NCT00735852
Drug: Decapeptyl SR 11.25mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 11.25 mgs, Intra muscular (IM) every 3 months for 2 years
Study: NCT00441298
Drug: Placebo (Universal HEC placebo)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be provided with a supply of single-use, pre-filled applicators according to their randomisation. While in the study, participants will be asked to apply a first dose of the assigned study product, placebo gel, within 12 hours prior to coitus and insert a second dose as soon as possible within 12 hours after coitus. They will be advised to use only two doses of gel in a 24-hour period.
Study: NCT02429089
Drug: LEE011
Approvals — FDA: no, EMA: no, PMDA: no
Description: The first 12 patients will receive cetuximab associated with LEE011 at doses of 400 mg and 600 mg daily to determine the DLTs and safety.~In the expansion part, besides safety, objective response rate, progression-free survival and overall survival will be calculated with the inclusion of 14 patients.
Study: NCT00765830
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: qd
Study: NCT01320033
Drug: Doxycycline 100 mg
Normalized name: doxycycline 100 MG
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants receive 100 mg of Doxycycline capsule once a day for 16 weeks
Study: NCT01320033
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants receive matching placebo tablet, matching placebo capsule once a day for 16 weeks.
Study: NCT00446979
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: HEC (hydroxyethyl cellulose) Control Gel applied vaginally twice daily for two weeks
Study: NCT00446979
Drug: UC 781
Normalized name: Astri-UC
Approvals — FDA: no, EMA: no, PMDA: no
Description: UC 781 0.1% or UC 781 0.25%, applied vaginally twice daily for two intermenstrual weeks
Study: NCT03802201
Drug: PTG-300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (SC)
Study: NCT02062099
Drug: [18F]DPA-714 PET/ [18F]AV-45 PET/neuropsychological assessment
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04238793
Drug: KLS-2031
Approvals — FDA: no, EMA: no, PMDA: no
Description: KLS-2031 administered by transforaminal epidural injection
Study: NCT02825641
Drug: Dinoprostone
Normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Labor induction and cervical ripening by dinoprostone in women with premature rupture of membranes in 2 types of women:~1. Induction of labor on presentation at the delivery room.~2. Induction of labor after 24 hours of rupture of membranes.
Study: NCT00914095
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablets of placebo 3 times a day
Study: NCT01602640
Drug: Fentanyl and Midazolam infusion
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Conventional dose
Study: NCT03898024
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: water injection; Route of administration: subcutaneous
Study: NCT03110549
Drug: TMB-607
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03110549
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02705547
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Daily oral administration of Rosuvastatin (10 mg) for 3 months
Study: NCT00369564
Drug: glutamic acid
Normalized name: Glutamic Acid
DrugBank: Glutamic acid (DB00142)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally 3 times daily
Study: NCT02850744
Drug: PQR309
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80mg capsules p.o. once daily and possibly Standard Treatment with temozolomide
Study: NCT02532998
Drug: AZD9977 oral suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD9977 oral suspension, single dose
Study: NCT02532998
Drug: AZD9977 placebo oral suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral suspension, single dose
Study: NCT02532998
Drug: Eplerenone, tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg (2 x 50 mg tablets) single dose, may be modified based on emerging data (will not exceed 500 mg per treatment period)
Study: NCT00004885
Drug: FOLFIRI regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00004885
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01400698
Drug: Saizen® A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous or intermittent treatment with recombinant human Growth Hormone (r-hGH) 0.067 milligram/kilogram/day (mg/kg/day) subcutaneously (sc).
Study: NCT01400698
Drug: Saizen® B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Observed until the first signs of puberty and then continuous treatment with r-hGH 0.067 mg/kg/day sc or observed without treatment.
Study: NCT00004885
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04265027
Drug: 50 mg BIA 9 1067
Normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hard Capsule; Oral
Study: NCT04265027
Drug: 25 mg BIA9 1067
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hard Capsule; Oral
Study: NCT03172234
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: in control group : the patients will receive Placebo Oral Tablet 90 minute prior to the surgery
Study: NCT01920087
Drug: ATNC05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subject will take between two and four capsules of study medication per day, according to the dose titration schedule in the protocol.
Study: NCT01920087
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subject will take between two and four capsules of study medication per day, according to the dose titration schedule in the protocol.
Study: NCT00663364
Drug: Physiogel AI Lotion, Physiogel Lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiogel AI Lotion and Physiogel Lotion is a cosmetic, applied twice daily to dry skin
Study: NCT01426009
Drug: Placebo EP-101
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo EP-101 administered once daily for 7 days
Study: NCT01426009
Drug: EP-101 via nebulizer (eFlow®) 200 ug
Approvals — FDA: no, EMA: no, PMDA: no
Description: EP-101 (200) ug administered once daily for 7 days
Study: NCT01610297
Drug: ICL670
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dose of ICL670 at 10 mg/kg daily
Study: NCT05293808
Drug: aspirin 100 mg once daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient will be randomized and after 10 days and 30 days we will measure platelets aggregation.
Study: NCT02449915
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: At the completion of the procedure, and at least 20 minutes after the injection of lidocaine with epinephrine (routine for the surgical procedure), those subjects in the placebo arm will have 30mL total volume injected. Ten mL will be injected into the perineum in the posterior vaginal area and 20 mL will be injected the port site wounds in the abdomen (5 sites, 4 ml per incision).
Study: NCT00451074
Drug: Gentamicin infusions twice a week for six months
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin infusions twice a week
Study: NCT00681902
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jet saline
Study: NCT04063540
Drug: Amiloride
Normalized name: Amiloride
DrugBank: Amiloride (DB00594)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment by Amiloride vs placebo in crossover
Study: NCT00117026
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for benfotiamine